Healthcare provider profile · identity verified

Scott E Jenkins, MD

Internal Medicine · NEWPORT BEACH, CA · NPI 1528009743

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	681	182
Rosuvastatin Calcium	Rosuvastatin Calcium	481	132
Levothyroxine Sodium	Levothyroxine Sodium	393	97
Amlodipine Besylate	Amlodipine Besylate	363	94
Valsartan	Valsartan	244	68
Metoprolol Succinate	Metoprolol Succinate	240	72
Eliquis	Apixaban	233	49
Escitalopram Oxalate	Escitalopram Oxalate	201	48
Losartan Potassium	Losartan Potassium	199	51
Ezetimibe	Ezetimibe	162	56
Tamsulosin Hcl	Tamsulosin Hcl	162	45
Trazodone Hcl	Trazodone Hcl	155	37
Famotidine	Famotidine	152	27
Olmesartan Medoxomil	Olmesartan Medoxomil	138	35
Allopurinol	Allopurinol	135	34
Furosemide	Furosemide	129	33
Lisinopril	Lisinopril	124	31
Irbesartan	Irbesartan	123	34
Synthroid	Levothyroxine Sodium	121	30
Finasteride	Finasteride	120	28
Zolpidem Tartrate	Zolpidem Tartrate	118	35
Gabapentin	Gabapentin	117	38
Simvastatin	Simvastatin	114	28
Metformin Hcl	Metformin Hcl	108	30
Azithromycin	Azithromycin	103	86
Pantoprazole Sodium	Pantoprazole Sodium	98	33
Omeprazole	Omeprazole	95	25
Trulicity	Dulaglutide	89	13
Montelukast Sodium	Montelukast Sodium	76	25
Hydrochlorothiazide	Hydrochlorothiazide	75	24
Donepezil Hcl	Donepezil Hcl	74	20
Fluticasone Propionate	Fluticasone Propionate	73	25
Clopidogrel	Clopidogrel Bisulfate	72	22
Ozempic	Semaglutide	71	suppressed
Alprazolam	Alprazolam	66	25
Midodrine Hcl	Midodrine Hcl	63	16
Nebivolol Hcl	Nebivolol Hcl	60	15
Warfarin Sodium	Warfarin Sodium	60	suppressed
Farxiga	Dapagliflozin Propanediol	59	13
Ramipril	Ramipril	58	12
Alendronate Sodium	Alendronate Sodium	56	21
Hydralazine Hcl	Hydralazine Hcl	55	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	55	43
Januvia	Sitagliptin Phosphate	54	14
Telmisartan	Telmisartan	54	15
Tramadol Hcl	Tramadol Hcl	53	15
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	53	12
Atenolol	Atenolol	51	14
Cefuroxime	Cefuroxime Axetil	50	43
Meloxicam	Meloxicam	50	11
Memantine Hcl	Memantine Hcl	48	suppressed
Prolia	Denosumab	45	30
Baclofen	Baclofen	44	suppressed
Bupropion Xl	Bupropion Hcl	43	12
Paxlovid	Nirmatrelvir/Ritonavir	43	43
Xarelto	Rivaroxaban	43	14
Metoprolol Tartrate	Metoprolol Tartrate	42	12
Azelastine Hcl	Azelastine Hcl	40	12
Estradiol	Estradiol	37	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	36	24
Potassium Chloride	Potassium Chloride	34	suppressed
Repatha Sureclick	Evolocumab	34	suppressed
Fluocinonide	Fluocinonide	32	24
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Spironolactone	Spironolactone	31	suppressed
Celecoxib	Celecoxib	30	suppressed
Myrbetriq	Mirabegron	30	suppressed
Acyclovir	Acyclovir	29	13
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Carvedilol	Carvedilol	28	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Valacyclovir	Valacyclovir Hcl	26	13
Edarbi	Azilsartan Medoxomil	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	14
Methylprednisolone	Methylprednisolone	24	22
Sertraline Hcl	Sertraline Hcl	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	18
Jardiance	Empagliflozin	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	21	14
Lovastatin	Lovastatin	21	suppressed
Metformin Hcl Er	Metformin Hcl	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	17
Primidone	Primidone	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Amoxicillin	Amoxicillin	20	13
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Dexlansoprazole Dr	Dexlansoprazole	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	12
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	15	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Cephalexin	Cephalexin	15	15
Clonazepam	Clonazepam	15	suppressed
Prednisone	Prednisone	15	suppressed
Rivastigmine	Rivastigmine	15	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Lagevrio (Eua)	Molnupiravir	13	13
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Erythromycin	Erythromycin Base	12	12
Eszopiclone	Eszopiclone	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Topiramate	Topiramate	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error